Safety profile and adverse drug reactions with causality assessment of Ticagrelor in Myocardial Infraction
Introduction: Antiplatelet medications are the most commonly used first-line therapy in acute coronary syndrome (ACS), particularly those undergoing percutaneous coronary intervention (PCI).P2Y12 is one of the two platelet receptors for adenosine diphosphate (ADP), which play a very important role in platelet function and thrombus formation.
Method: In this article, we present 2 case reports of patients, showing severe symptoms of dyspnoea. Then we describe possible mechanisms of these complications when switching Ticagrelor to other antiplatelet drugs, and also make therapeutic recommendations for Ticagrelor-associated therapy based on what we know presently to deal with such symptoms.
Results: In ACS patients, with existing respiratory disorders, Dyspnoea can be fatal. Clinical studies have shown that reduced lung function or low EF is not harmful contraindications for Ticagrelor.
Discussion: However, these groups of patients should be monitored closely after administration of Ticagrelor.
Cannon, C. P., Husted, S., Harrington, R. A., Scirica, B. M., Emanuelsson, H., Peters, G., Storey, R. F., & DISPERSE-2 Investigators (2007). Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. Journal of the American College of Cardiology, 50(19), 1844–1851.
Cattaneo M. (2010) New P2Y12 Inhibitors. Circulation, 121(1), 171–179.
Cattaneo M. (2011). The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects. Blood, 117(7), 2102–2112.
Hamm, C. W., Bassand, J. P., Agewall, S., Bax, J., Boersma, E., Bueno, H., Caso, P., Dudek, D., Gielen, S., Huber, K., Ohman, M., Petrie, M. C., Sonntag, F., Uva, M. S., Storey, R. F., Wijns, W., Zahger, D., & ESC Committee for Practice Guidelines (2011). ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European heart journal, 32(23), 2999–3054.
Husted, S., Emanuelsson, H., Heptinstall, S., Sandset, P. M., Wickens, M., & Peters, G. (2006). Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. European heart journal, 27(9), 1038–1047.
Krakowiak, A., Kuleta, J., Plech, I., Zarębiński, M., Wojciechowska, M., Wretowski, D., & Cudnoch-Jędrzejewska, A. (2020). Ticagrelor-Related Severe Dyspnoea: Mechanisms, Characteristic Features, Differential Diagnosis and Treatment. Clinical medicine insights. Case reports, 13, 1179547620956634.
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981). A method for estimating the probability of adverse drug reactions. Clinical pharmacology and therapeutics, 30(2), 239–245.
Parodi, G., & Storey, R. F. (2015). Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. European heart journal. Acute cardiovascular care, 4(6), 555–560.
Steg, P. G., James, S. K., Atar, D., Badano, L. P., Blömstrom-Lundqvist, C., Borger, M. A., Di Mario, C., Dickstein, K., Ducrocq, G., Fernandez-Aviles, F., Gershlick, A. H., Giannuzzi, P., Halvorsen, S., Huber, K., Juni, P., Kastrati, A., Knuuti, J., Lenzen, M. J., Mahaffey, K. W., … Zahger, D. (2012). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European heart journal, 33(20), 2569–2619.
Storey, R. F., Becker, R. C., Harrington, R. A., Husted, S., James, S. K., Cools, F., Steg, P. G., Khurmi, N. S., Emanuelsson, H., Cooper, A., Cairns, R., Cannon, C. P., & Wallentin, L. (2011). Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. European heart journal, 32(23), 2945–2953.
The use of the WHO–UMC system for standardized case causality assessment <https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf>
Zhang, N., Xu, W., Li, O., & Zhang, B. (2020). The risk of dyspnea in patients treated with third-generation P2Y12 inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials. BMC cardiovascular disorders, 20(1), 140.
Copyright (c) 2022 S. P. Santhosh Kumar , Shangavi V, Abisha R S, M. S. Aiswaria , Abburi Lalitha Nandini, Abitha Aravindakshan, Amritha Harish N
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.